Phenotypes of irritable bowel syndrome and strategies for patient-oriented curation of patient

Objective. To propose a patient-oriented approach to the management of a patient with irritable bowel syndrome based on the identified phenotypes of the disease.

Materials and methods. Based on a comprehensive analysis of the interaction of genetic and epigenetic factors, the characteristics of the phenotypes of irritable bowel syndrome have been identified and presented. For each phenotype, individualized treatment regimens for the disease have been developed and tested. To evaluate the effectiveness of the proposed patient-oriented approaches, an open cohort, prospective, randomized study in parallel groups was conducted.

Results. With post-infectious irritable bowel syndrome, patients are recommended to prescribe a strain of Lactobacillus paracasei CNCMI1572, as well as correction of eating habits with restriction of salt and products containing lactose. With the phenotype of irritable bowel syndrome with overweight and obesity, patients were offered the restriction of foods with a high glycemic index, the additional appointment of ademetionine, as well as a synbiotic containing inulin, strains of Bifidobacteriumlactis Bl-04, Lactobacillusacidophilus La-14, Lactobacillusrhamnosus Lr-32 and B vitamins In the comorbid phenotype, it is advisable to prescribe the cytoprotector rebamipide. Additionally, a correction of the diet is necessary with the exclusion of trigger foods. With the essential phenotype, patients are recommended to take the probiotic strain Bifidobacterium longum 35624. The use of the proposed patient-oriented strategies in addition to standard therapy made it possible to achieve more effective relief of clinical manifestations and reduce the severity of irritable bowel syndrome, improve mental well-being, and reduce the frequency of relapses of the disease.

Conclusion. The proposed patient-oriented approaches to the management of a patient with irritable bowel syndrome based on the identified disease phenotypes can be considered as one of the possible ways to improve the effectiveness of disease therapy.

1. Black C. J., Ford A. C. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat. Rev. Gastroenterol. Hepatol. 2020; 17 (8): 473-486. DOI: 10.1038/s41575-020-0286-8.

2. Lacy B. E., Patel N. K. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J. Clin. Med. 2017; 6 (11): 99. DOI: 10.3390/jcm6110099.

3. Flacco M. E., Manzoli L., De Giorgio R., et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. Eur. Rev. Med Pharmacol. Sci. 2019; 23 (7): 2986-3000. DOI: 10.26355/ eurrev_201904_17580.

4. Nellesen D., Yee K., Chawla A., Lewis B. E., Carson R. T. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J. Manag. Care. Pharm. 2013; 19 (9): 755-764. DOI: 10.18553/jmcp.2013.19.9.755.

5. Zhang F., Xiang W., Li C. Y., Li S. C. Economic burden of irritable bowel syndrome in China. World. J. Gastroenterol. 2016; 22 (47): 10450-10460. DOI: 10.3748/wjg.v22.i47.10450.

6. Ivashkin V. T., Maev I. V., Shelygin Yu. A. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Ros. zhur. gastroenterol., gepatol., koloproktol. 2021; 31 (5): 74-95. DOI: 10.22416/1382-4376-2021-31-5-74-95. (In Russ.)

7. WHO Europe. CINDI Health Monitor: A Study of feasibility of a health behaviour monitoring survey across CINDI countries. Available at: http://www.euro.who. int/__data/assets/pdf_file/0017/240236/e79396.pdf (access date: 25 June 2023).

8. Erofeev Ju. V., Boldyreva M. S., Turchaninov D. V., et al. Organization and methods of conducting sociological studies of the health of the rural population for information support of the system of social and hygienic monitoring: Method. recommendations. Omsk: FGU CGSJeN Omsk region, 2004. (In Russ.)

9. Zigmond A. S., Snaith R. P. The hospital anxiety and depression scale // Acta. Psychiatr. Scand. 1983; 67 (6): 361-370. DOI: 10.1111/j.1600-0447.1983.tb09716.

10. Labus J. S., Bolus R., Chang L., et al. The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale // Aliment. Pharmacol. Ther. 2004; 20 (1): 89-97. DOI: 10.1111/j.1365-2036.2004.02007.

11. Drossman D. A., Patrick D. L., Whitehead W. E., et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am. J. Gastroenterol. 2000; 95 (4): 999-1007. DOI: 10.1111/j.1572-0241.2000.01941.x.

12. Gaus O. V., Livzan M. A. Irritable bowel syndrome phenotypes: leading factors of genetics and epigenetics, mechanisms of formation. Ter. Arkh. 2023; 95 (2): 164-172. DOI: 10.26442/00403660.2023.02.202111. (In Russ.)

13. Gaus O. V., Livzan M. A. Genetic factors and the course of irritable bowel syndrome: associations and interactions. RMZh. Meditsinskoe obozrenie. 2023; 7 (5): 237-248. DOI: 10.32364/2587-6821-2023-7-5-1. (In Russ.)

14. Bengtsson M., Ohlsson B., Ulander K. Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS). BMC Gastroenterol. 2007; 7: 16. DOI: 10.1186/1471-230X-7-16.

15. Francis C. Y., Morris J., Whorwell P. J. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997; 11 (2): 395-402. DOI: 10.1046/j.1365-2036.1997.142318000.x.

16. Zakostelska Z., Kverka M., Klimesova K., et al. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS One. 2011; 6 (11): e27961. DOI: 10.1371/journal.pone.0027961.

17. Ferrario C., Taverniti V., Milani C., et al. Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. J. Nutr. 2014; 144 (11): 1787-1796. DOI: 10.3945/jn.114.197723.

18. D'Incà R., Barollo M., Scarpa M., et al. Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. Dig. Dis. Sci. 2011; 56 (4): 1178-1187. DOI: 10.1007/s10620-010-1384-1.

19. Cremon C., Guglielmetti S., Gargari G., et al. Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United. European. Gastroenterol. J. 2018; 6(4): 604-613. DOI: 10.1177/2050640617736478.

20. Asadi A., Shadab Mehr N., Mohamadi M. H., et al. Obesity and gut-microbiotabrain axis: A narrative review. J. Clin. Lab. Anal. 2022; 36 (5): e24420. DOI: 10.1002/jcla.24420.

21. Geurts L., Neyrinck A. M., Delzenne N. M., et al. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Benef Microbes. 2014; 5 (1): 3-17. DOI: 10.3920/BM2012.0065.

22. Torres-Fuentes C., Schellekens H., Dinan T. G., Cryan J. F. A natural solution for obesity: bioactives for the prevention and treatment of weight gain. A review. Nutr. Neurosci. 2015; 18 (2): 49-65. DOI: 10.1179/1476830513Y.0000000099.

23. Popkin B. M., Gordon-Larsen P. The nutrition transition: worldwide obesity dynamics and their determinants. Int. J. Obes. Relat. Metab. Disord. 2004; 28 Suppl 3: S2-S9. DOI: 10.1038/sj.ijo.0802804.

24. Natividad J. M., Lamas B., Pham H. P., et al. Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice. Nat. Commun. 2018; 9(1): 2802. DOI: 10.1038/s41467-018-05249-7.

25. Vijayvargiya P., Busciglio I., Burton D., et al. Bile acid deficiency in a subgroup of patients with irritable bowel syndrome with constipation based on biomarkers in serum and fecal samples. Clin. Gastroenterol. Hepatol. 2018; 16 (4): 522-527. DOI: 10.1016/j.cgh.2017.06.039.

26. Wilson A. S-Adenosyl Methionine (SAMe) for Depression in Adults. Issues. Ment. Health. Nurs. 2019; 40 (8): 725-726. DOI: 10.1080/01612840.2017.1392161.

27. Singh R., Zogg H., Ghoshal U. C., Ro S. Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders. Front. Pharmacol. 2022; 13: 808195. DOI: 10.3389/fphar.2022.808195.

28. Lee J. S., Jeon S. W., Lee H. S., et al. Rebamipide for the Improvement of Gastric Atrophy and Intestinal Metaplasia: A Prospective, Randomized, Pilot Study. Dig. Dis. Sci. 2022; 67 (6): 2395-2402. DOI: 10.1007/s10620-021-07038-7.

29. Jaafar M. H., Safi S. Z., Tan M. P., et al. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig. Dis Sci. 2018; 63 (5): 1250-1260. DOI: 10.1007/s10620-017-4871-9.

30. O'Mahony L., McCarthy J., Kelly P., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005; 128 (3): 541-551. DOI: 10.1053/j.gastro.2004.11.050.